Loading clinical trials...
Loading clinical trials...
A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease
Conditions
Interventions
PF-02545920
PF-02545920
+1 more
Locations
57
United States
The Kirklin Clinic of UAB Hospital
Birmingham, Alabama, United States
The University of Alabama at Birmingham
Birmingham, Alabama, United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
Mayo Clinic Arizona
Phoenix, Arizona, United States
Mayo Clinic Arizona
Scottsdale, Arizona, United States
University of California, Irvine
Irvine, California, United States
Start Date
September 1, 2014
Primary Completion Date
September 1, 2016
Completion Date
October 1, 2016
Last Updated
November 17, 2017
NCT02855476
NCT01574053
NCT04120493
NCT05107128
NCT03664804
NCT00670709
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions